The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
5-hydroxymethylcytosine as a liquid biopsy biomarker in mCRPC.
 
Martin Sjöström
Research Funding - PFS Genomics (Inst); PFS Genomics (Inst)
 
Shuang Zhao
Employment - PFS Genomics (I)
Leadership - PFS Genomics (I)
Patents, Royalties, Other Intellectual Property - Patent applications on genomic signatures in prostate cancer with GenomeDx Biosciences, Celgene, PFS Genomics
 
Eric Jay Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics
Honoraria - Janssen
Consulting or Advisory Role - Beigene; Fortis; Janssen Oncology; Teon Therapeutics; Tolero Pharmaceuticals
Research Funding - Janssen (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Janssen
 
Yuhong Ning
Employment - Bluestar Genomics
Stock and Other Ownership Interests - Bluestar Genomics
Patents, Royalties, Other Intellectual Property - Bluestar Genomics
 
Corinne Maurice-Dror
Speakers' Bureau - Bristol-Myers Squibb; Medison; MSD; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Medison; Novartis; Pfizer
 
Adam Foye
No Relationships to Disclose
 
Jun Jie T. Hua
No Relationships to Disclose
 
Haolong Li
No Relationships to Disclose
 
Tomasz M. Beer
Stock and Other Ownership Interests - Arvinas; Salarius Pharmaceuticals
Consulting or Advisory Role - Arvinas; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Constellation Pharmaceuticals; GlaxoSmithKline; GRAIL; Novartis; Pfizer; Sanofi; Tolero Pharmaceuticals
Research Funding - Alliance Foundation Trials (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Freenome (Inst); GRAIL (Inst); Harpoon Therapeutics (Inst); Janssen Research & Development (Inst); Medivation (Inst); Sotio (Inst); Theraclone Sciences (Inst); Zenith Epigenetics (Inst)
 
Christopher P. Evans
Speakers' Bureau - Astellas Pharma; Janssen Oncology; Pfizer
Research Funding - Anchiano; Astellas Pharma; Janssen Research & Development
 
Matthew Rettig
Consulting or Advisory Role - Ambrx; Amgen; Clovis Oncology; Johnson & Johnson
Speakers' Bureau - Bayer; Johnson & Johnson
Research Funding - Johnson & Johnson (Inst); Medivation/Astellas (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for novel inhibitors of the N-terminal domain of the AR. There are NO commercial partnerships as of yet.
Travel, Accommodations, Expenses - Johnson & Johnson
 
Kim N. Chi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Constellation Pharmaceuticals; Daiichi Sankyo; ESSA; Janssen; Merck; POINT Biopharma; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
 
Joshi J. Alumkal
Consulting or Advisory Role - Dendreon; Merck Sharp & Dohme
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Gilead Sciences (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Merck Sharp & Dohme
Other Relationship - Astellas Pharma
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - AstraZeneca; Dendreon; Janssen
Research Funding - Abbvie (Inst); Amgen (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Xynomic Pharma
 
Alan Ashworth
Leadership - Cambridge Science Corporation
Stock and Other Ownership Interests - Azkarra Therapeutics; Bluestar Genomics; Cambridge Science Corporation; Circle Pharma; Earli; Gladiator Biosciences; OVIBIO; ProLynx; Tango Therapeutics
Consulting or Advisory Role - Azkarra Therapeutics; Bluestar Genomics; Cambridge Science Corporation; Circle Pharma; Cura Therapeutics; Earli; Genentech; GenVivo; Gladiator Biosciences; OVIBIO; ProLynx; Tango Therapeutics
Research Funding - AstraZeneca; SPARC
Patents, Royalties, Other Intellectual Property - AstraZeneca, related to PARP inhibitors
 
Samuel Levy
Employment - Bluestar Genomics
Leadership - Bluestar Genomics
Stock and Other Ownership Interests - Bluestar Genomics
Patents, Royalties, Other Intellectual Property - Bluestar Genomics
 
Housheng H. He
Stock and Other Ownership Interests - Guardant Health
Honoraria - Illumina
Patents, Royalties, Other Intellectual Property - US62/700,436 (Inst); US63/006,455 (Inst)
 
Alexander W. Wyatt
Honoraria - Bayer; Janssen
Consulting or Advisory Role - AstraZeneca
Research Funding - Janssen
 
David A. Quigley
No Relationships to Disclose
 
Felix Y Feng
Leadership - PFS Genomics
Stock and Other Ownership Interests - PFS Genomics
Honoraria - Genentech
Consulting or Advisory Role - Astellas Pharma; Blue Earth Diagnostics; Celgene; Genentech; Janssen Biotech; Myovant Sciences; Roivant; SerImmune
Research Funding - Zenith Epigenetics
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst)